Oncimmune Holdings PLC Change of Adviser (0026R)
02 November 2021 - 6:00PM
UK Regulatory
TIDMONC
RNS Number : 0026R
Oncimmune Holdings PLC
02 November 2021
2 November 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Change of Adviser
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, announces the appointment of Singer
Capital Markets as nominated adviser and joint broker, with
immediate effect. WG Partners will continue to support the Company
in its role as joint broker.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Nigel Birks
+44 (0)20 3705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue base, both from its portfolio of diagnostic
products to detect early-stage cancer and its contract discovery
and development service business whose platform delivers actionable
insights into therapies to the Company's pharmaceutical and biotech
partners .
Our understanding of the immune system enables us to harness its
sophisticated response to disease to detect cancer earlier and to
support the development of better therapies. The key to improving
cancer survival is early detection and better selection for
therapy. As a company, we are driven by our passion to improve
cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effectively targeted and safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune is headquartered at its EarlyCDT product and R&D
laboratory facility in Nottingham, UK and its ImmunoINSIGHTS pharma
services commercial laboratory facility is based in Dortmund,
Germany. The ImmunoINSIGHTS Commercial Team is based in the US and
Europe.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPKZMGMZZGGMZG
(END) Dow Jones Newswires
November 02, 2021 03:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024